EP 3472316 A1 20190424 - ANTI-C5 ANTIBODIES AND METHODS OF USE
Title (en)
ANTI-C5 ANTIBODIES AND METHODS OF USE
Title (de)
ANTI-C5-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG
Title (fr)
ANTICORPS ANTI-C5 ET LEURS PROCÉDÉS D'UTILISATION
Publication
Application
Priority
- JP 2016120325 A 20160617
- JP 2017022253 W 20170616
Abstract (en)
[origin: WO2017217524A1] The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the beta chain of C5 with a higher affinity at neutral pH than at acidic pH. The invention also provides isolated nucleic acids encoding an anti-C5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention so that the antibody is produced. The invention further provides a method of producing an anti-C5 antibody comprising immunizing an animal against a polypeptide which comprises the MG1-MG2 domain of the beta chain of C5. Anti-C5 antibodies of the present invention may be for use as a medicament.
IPC 8 full level
C12N 15/09 (2006.01); A61K 39/395 (2006.01); A61P 7/00 (2006.01); C07K 16/18 (2006.01)
CPC (source: EP IL KR)
A61P 7/00 (2018.01 - EP IL); C07K 16/18 (2013.01 - EP IL KR); A61K 2039/505 (2013.01 - EP IL KR); C07K 2317/24 (2013.01 - EP IL KR); C07K 2317/33 (2013.01 - EP IL); C07K 2317/34 (2013.01 - EP IL); C07K 2317/55 (2013.01 - KR); C07K 2317/56 (2013.01 - EP IL KR); C07K 2317/567 (2013.01 - KR); C07K 2317/76 (2013.01 - EP IL KR); C07K 2317/92 (2013.01 - EP IL KR); C07K 2317/94 (2013.01 - EP IL)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017217524 A1 20171221; AU 2017285763 A1 20181108; AU 2017285763 B2 20240201; BR 112018075688 A2 20190402; CA 3021956 A1 20171221; CL 2018003573 A1 20190201; CN 109312326 A 20190205; CN 109312326 B 20220909; CN 115925922 A 20230407; CN 115960223 A 20230414; CR 20190013 A 20190305; EA 201990018 A1 20190830; EP 3472316 A1 20190424; EP 3472316 A4 20200108; IL 263657 A 20190131; IL 300611 A 20230401; JP 2017226655 A 20171228; JP 2018009021 A 20180118; JP 2022091748 A 20220621; JP 6202774 B1 20170927; JP 7032077 B2 20220308; KR 101852739 B1 20180430; KR 102226975 B1 20210311; KR 20190009273 A 20190128; MX 2018015030 A 20190422; MX 2023001360 A 20230227; MY 187848 A 20211026; PE 20190394 A1 20190313; PE 20240825 A1 20240418; PH 12018502354 A1 20190923; RU 2019100222 A 20200717; RU 2019100222 A3 20201105; SG 10201800265U A 20180227; SG 11201705584V A 20180530; TW 201808996 A 20180316; TW 201809000 A 20180316; TW 202239766 A 20221016; TW 202337903 A 20231001; TW I610941 B 20180111; TW I789369 B 20230111; TW I807666 B 20230701; UA 126561 C2 20221102
DOCDB simple family (application)
JP 2017022253 W 20170616; AU 2017285763 A 20170616; BR 112018075688 A 20170616; CA 3021956 A 20170616; CL 2018003573 A 20181212; CN 201780036916 A 20170616; CN 202211018018 A 20170616; CN 202211023851 A 20170616; CR 20190013 A 20170616; EA 201990018 A 20170616; EP 17813418 A 20170616; IL 26365718 A 20181212; IL 30061123 A 20230213; JP 2017118226 A 20170616; JP 2017162934 A 20170828; JP 2022026406 A 20220224; KR 20177020545 A 20170616; KR 20187010179 A 20170616; MX 2018015030 A 20170616; MX 2023001360 A 20181204; MY PI2018002581 A 20170616; PE 2018003148 A 20170616; PE 2023002969 A 20170616; PH 12018502354 A 20181108; RU 2019100222 A 20170616; SG 10201800265U A 20170616; SG 11201705584V A 20170616; TW 106120143 A 20170616; TW 106141573 A 20170616; TW 111107923 A 20170616; TW 112120479 A 20170616; UA A201810992 A 20170616